secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVAI BIO, INC. (AVAI)
CIK:        0001740797
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001740797-24-000056
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avant to fund up to $20M, forms 50/50 JV with Ainnova for retina AI tech
------------------------------------------------------------------------

- Avant contributes up to $20M in capital over 12 months to new JV 'Ai-Nova Acquisition Corp'.
- Ainnova contributes Vision AI technology portfolio for retinal disease detection and scanning.
- Ownership split 50% Avant, 50% Ainnova; JV to issue 2,000,000 shares.
- Profit distribution: first to Ainnova for contributed business value, then Avant for capital, then pro-rata.
- Territories include US, Canada, Europe; JV to seek third-party licensing and strategic transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740797/000174079724000056/0001740797-24-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740797/000174079724000056/report8k_avai.htm
  HTML page:      https://secwatch.observer/filing/0001740797-24-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer